Anzeige
Mehr »
Freitag, 11.07.2025 - Börsentäglich über 12.000 News
Der nächste Volltreffer direkt neben einer brandneuen Entdeckung! Kupfer im Höhenflug!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
203 Leser
Artikel bewerten:
(1)

BCC Research LLC: BCC Research Presents 2024 Diagnostics Research Review: Market Growth and Innovations

"Exploring Resilient Growth and Technological Advances in the Global Diagnostics Market Amid Economic Challenges and Post-Pandemic Recovery"

BOSTON, July 11, 2025 /PRNewswire/ -- BCC Research announces the release of its "2024 Diagnostics Research Review," shining a spotlight on the significant growth of and advances in the global diagnostics market. The review provides insights into various segments, including AI in clinical and molecular diagnostics, companion diagnostics, and drugs and diagnostics for hematological disorders.

BCC Research Logo

Highlights:

  • AI in Clinical and Molecular Diagnostics Market:
    - The market is projected to grow from $2.6 billion in 2024 to $8.9 billion by the end of 2029.
    - Compound Annual Growth Rate (CAGR): 27.6%.

  • Companion Diagnostics: Technologies and Market:
    - The market is projected to grow from $7.6 billion in 2023 to $15.4 billion by the end of 2028.
    - CAGR: 15.2%.

  • Drugs and Diagnostics for Hematological Disorders: Global Market:
    - The market is projected to grow from $131.2 billion in 2024 to $189.3 billion by the end of 2029.
    - CAGR: 7.6%.

Research Coverage and Insights

The diagnostics industry has shown remarkable resilience and growth despite challenging economic conditions. This sector is currently undergoing significant changes driven by an evolving regulatory focus and the emergence of new markets. Here are key insights from the latest research:

  • Growth Amid Economic Challenges: The diagnostics industry has continued to grow despite challenging economic conditions, drawing significant attention from the public and government.

  • Regulatory Changes: The industry is undergoing many changes due to an increased focus on regulations, with the U.S. leading the trend to make healthcare more affordable.

  • Emerging Markets: New opportunities for the diagnostic industry are arising in emerging economies.

  • Increased Demand: Rising healthcare expenditures and the growth of emerging economies have increased the demand for technologically advanced diagnostic devices, kits, reagents, and other accessories.

  • Stringent Regulations: More stringent regulations in developed markets like the U.S. and Europe have pushed diagnostics manufacturers to develop products with new materials and in-depth indications.

  • Competitive Landscape: The highly competitive market requires companies to continuously reinvent their product portfolios to enter new markets and establish themselves as significant players in the healthcare system.

  • Value-Based Healthcare: There is a shift towards a value-based healthcare market where price and purchase decisions are based on outcomes, leading to increased scrutiny of device technology and heightened competition.

  • Major Players: Major players in the diagnostics market include Abbott, Medtronic, F. Hoffmann-La Roche, Siemens Healthineers, GE Healthcare, Koninklijke Philips, Agilent Technologies, Qiagen, Danaher, Sysmex, Thermo Fisher Scientific, BD, and Becton Dickinson.

  • Market Outlook: The diagnostics industry's growth will depend on its ability to provide lower-cost technology for home healthcare and to develop user-friendly diagnostic devices for individuals with minimal healthcare experience.

  • Post-COVID-19 Impact: The global pandemic has both positively and negatively impacted the diagnostics industry, highlighting the need for state-of-the-arttechnology and equipment. The market is now dealing with the fallout from COVID-19 and its effects on the global diagnostics landscape.

Research Summary:

BCC Research is a leading provider of market research reports and insights, helping businesses make informed decisions. Our 2024 Diagnostics Research Review includes detailed analyses from reports such as:

  • BIO261A AI in Clinical and Molecular Diagnostics Market

  • BIO077F Companion Diagnostics: Technologies and Global Markets

  • PHM116C Drugs and Diagnostics for Hematological Disorders Global Markets

  • BIO233B In Vitro Diagnostics (IVD) Quality Controls: Global Market

  • HLC043H Point of Care Diagnostics: Technologies and Global Markets

  • BIO157C Polymerase Chain Reaction (PCR) for Point of Care (POC) Diagnostics

  • PHM227B Rare Disease Diagnostics: Technologies and Global Markets

This Research Review provides a consolidated overview of market insights from these recent reports. The full reports referenced in this review offer additional depth on each topic, offering further context and more detailed analysis.

For further information on any of these reports or to make a purchase, contact info@bccresearch.com.

About BCC Research

BCC Research market research reports provide objective, unbiased measurement and assessment of market opportunities. Our experienced industry analysts' goal is to help you make informed business decisions free of noise and hype.

Contact Us

Corporate HQ: 50 Milk St., Ste. 16, Boston, MA 02109, USA
Email: info@bccresearch.com
Phone: +1 781-489-7301
For media inquiries, email press@bccresearch.com or visit our media page for access to our market research library.

Any data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher.

Logo - https://mma.prnewswire.com/media/2183242/5410860/BCC_Research_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/bcc-research-presents-2024-diagnostics-research-review-market-growth-and-innovations-302503236.html

© 2025 PR Newswire
Hensoldt, Renk & Rheinmetall teuer
Rheinmetall, Renk und Hensoldt haben den Rüstungsboom der letzten Jahre dominiert, doch inzwischen sind diese Titel fundamental heillos überbewertet. KGVs jenseits der 60, KUVs über 4, und das in einem politisch fragilen Umfeld mit wackelnder Haushaltsdisziplin. Für späteinsteigende Anleger kann das teuer werden.

Doch es gibt Alternativen, die bislang unter dem Radar fliegen; solide bewertet, operativ stark und mit Nachholpotenzial.

In unserem kostenlosen Report zeigen wir dir, welche 3 Rüstungsunternehmen noch Potenzial haben und wie du von der zweiten Welle der Zeitenwende profitieren kannst, ohne sich an überhitzten Highflyer zu verbrennen.

Holen Sie sich den neuesten Report! Verpassen Sie nicht, welche Aktien besonders vom weltweiten Aufrüsten profitieren dürften, und laden Sie sich das Gratis-PDF jetzt kostenlos herunter.

Dieses exklusive Angebot gilt aber nur für kurze Zeit! Daher jetzt downloaden!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.